PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Clinical trials for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) trials appear
Sign up with your email to follow new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial offers hope for Tough-to-Treat pancreatic cancer
Disease control Not yet recruitingThis study is testing an experimental drug called HLX43 in people with advanced pancreatic cancer that has continued to grow despite standard treatments. About 100 participants will receive the drug through an IV to see if it can shrink tumors and is safe to use. The main goals a…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Direct tumor attack: new method aims to boost pancreatic cancer surgery success
Disease control Not yet recruitingThis study is testing a new way to deliver a standard chemotherapy drug (gemcitabine) directly to pancreatic tumors before surgery. The goal is to see if this targeted delivery method is safe and can help surgeons remove more of the cancer with cleaner margins. It is for people w…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: University of Vermont • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug combo trial targets four tough digestive cancers
Disease control Not yet recruitingThis study is testing whether adding an experimental drug called SSGJ-706 to standard first-line chemotherapy can better control advanced cancers of the stomach, colon, pancreas, and esophagus. It will enroll about 300 adults with these cancers who have not yet received treatment…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for tough cancers: experimental drug targets key mutation
Disease control Not yet recruitingThis study is testing a new oral drug called BPI-572270 for people with advanced cancers that have specific RAS genetic mutations. Researchers want to find the safest and most effective dose, and see if it helps control cancers like lung, colorectal, and pancreatic cancer that ha…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Can a hand squeeze predict pancreatic cancer survival?
Knowledge-focused Not yet recruitingThis study aims to understand if a simple hand grip strength test can provide useful information for adults with pancreatic cancer. Researchers will ask 50 participants to squeeze a device during their regular clinic visits and fill out questionnaires about their well-being. The …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC
-
Does draining bile before surgery help or hurt pancreatic cancer patients?
Knowledge-focused Not yet recruitingThis study aims to understand if draining a blocked bile duct before pancreatic cancer surgery affects how the cancer spreads and patient survival. Researchers will review the medical records of over 90 patients who had surgery between 2014 and 2022, comparing those who had the d…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: East Lancashire Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC